Published in Cancer Res on September 15, 2008
PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res (2011) 4.80
Stimuli-responsive nanocarriers for drug delivery. Nat Mater (2013) 3.52
Akt3-mediated resistance to apoptosis in B-RAF-targeted melanoma cells. Cancer Res (2010) 2.42
Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma. Clin Cancer Res (2009) 2.21
Topical delivery of siRNA-based spherical nucleic acid nanoparticle conjugates for gene regulation. Proc Natl Acad Sci U S A (2012) 1.90
Raf family kinases: old dogs have learned new tricks. Genes Cancer (2011) 1.72
The PTEN-AKT3 signaling cascade as a therapeutic target in melanoma. Pigment Cell Melanoma Res (2009) 1.62
Transiently entrapped circulating tumor cells interact with neutrophils to facilitate lung metastasis development. Cancer Res (2010) 1.55
Integrating BRAF/MEK inhibitors into combination therapy for melanoma. Br J Cancer (2009) 1.48
Mining mammalian transcript data for functional long non-coding RNAs. PLoS One (2010) 1.46
Ultrasound-mediated transdermal drug delivery: mechanisms, scope, and emerging trends. J Control Release (2011) 1.41
Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail. Biochem Pharmacol (2010) 1.36
Lipidic systems for in vivo siRNA delivery. AAPS J (2009) 1.33
Targeting of survivin by nanoliposomal ceramide induces complete remission in a rat model of NK-LGL leukemia. Blood (2010) 1.09
A rapid and sensitive method to detect siRNA-mediated mRNA cleavage in vivo using 5' RACE and a molecular beacon probe. Nucleic Acids Res (2009) 1.02
Toxicological considerations when creating nanoparticle-based drugs and drug delivery systems. Expert Opin Drug Metab Toxicol (2011) 0.98
Low-frequency sonophoresis: application to the transdermal delivery of macromolecules and hydrophilic drugs. Expert Opin Drug Deliv (2010) 0.98
Melanoma chemoprevention in skin reconstructs and mouse xenografts using isoselenocyanate-4. Cancer Prev Res (Phila) (2010) 0.93
Fibroblast growth factor receptors as therapeutic targets in human melanoma: synergism with BRAF inhibition. J Invest Dermatol (2011) 0.92
Macrophage inhibitory cytokine-1 regulates melanoma vascular development. Am J Pathol (2010) 0.91
Identification of glycogen synthase kinase 3α as a therapeutic target in melanoma. Pigment Cell Melanoma Res (2013) 0.91
Genetics of melanoma. Front Genet (2013) 0.91
Current State of Animal (Mouse) Modeling in Melanoma Research. Cancer Growth Metastasis (2015) 0.91
Applications of nanotechnology for melanoma treatment, diagnosis, and theranostics. Int J Nanomedicine (2013) 0.90
Therapeutic implications of targeting the PI3Kinase/AKT/mTOR signaling module in melanoma therapy. Am J Cancer Res (2012) 0.90
Use of liposomes as drug delivery vehicles for treatment of melanoma. Pigment Cell Melanoma Res (2009) 0.90
The Akt signaling pathway: an emerging therapeutic target in malignant melanoma. Cancer Biol Ther (2011) 0.89
Targeted therapy for melanoma: a primer. Surg Oncol Clin N Am (2011) 0.89
Advanced targeted nanomedicine. J Biotechnol (2015) 0.87
The T-box transcription factor, TBX3, is a key substrate of AKT3 in melanomagenesis. Oncotarget (2015) 0.86
Selenium-containing histone deacetylase inhibitors for melanoma management. Cancer Biol Ther (2012) 0.86
Gene silencing following siRNA delivery to skin via coated steel microneedles: In vitro and in vivo proof-of-concept. J Control Release (2013) 0.86
Therapeutic Implications of Targeting AKT Signaling in Melanoma. Enzyme Res (2011) 0.85
Targeting sphingosine kinase-1 to inhibit melanoma. Pigment Cell Melanoma Res (2012) 0.85
Melanoma prevention using topical PBISe. Cancer Prev Res (Phila) (2011) 0.84
Inhibition of NADPH oxidase by glucosylceramide confers chemoresistance. Cancer Biol Ther (2010) 0.84
Sonoporation delivery of monoclonal antibodies against human papillomavirus 16 E6 restores p53 expression in transformed cervical keratinocytes. PLoS One (2012) 0.83
Simultaneous targeting of COX-2 and AKT using selenocoxib-1-GSH to inhibit melanoma. Mol Cancer Ther (2012) 0.82
Gene Silencing in Skin After Deposition of Self-Delivery siRNA With a Motorized Microneedle Array Device. Mol Ther Nucleic Acids (2013) 0.82
Ceramide kinase regulates TNFα-stimulated NADPH oxidase activity and eicosanoid biosynthesis in neuroblastoma cells. Cell Signal (2011) 0.81
Current and future trials of targeted therapies in cutaneous melanoma. Adv Exp Med Biol (2013) 0.81
Targeting multiple key signaling pathways in melanoma using leelamine. Mol Cancer Ther (2014) 0.81
PTEN gene: a model for genetic diseases in dermatology. ScientificWorldJournal (2012) 0.81
A Micro/Nano Composite for Combination Treatment of Melanoma Lung Metastasis. Adv Healthc Mater (2016) 0.80
Use of Nanotechnology to Develop Multi-Drug Inhibitors For Cancer Therapy. J Nanomed Nanotechnol (2013) 0.80
Drug delivery nanoparticles in skin cancers. Biomed Res Int (2014) 0.80
Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas. J Transl Med (2015) 0.77
Nanolipolee-007, a novel nanoparticle-based drug containing leelamine for the treatment of melanoma. Mol Cancer Ther (2014) 0.77
Optimization and apoptosis induction by RNAi with UTMD technology in vitro. Oncol Lett (2012) 0.76
Engineered Nanoparticles Against MDR in Cancer: The State of the Art and its Prospective. Curr Pharm Des (2016) 0.75
Ultrasound-enhanced transdermal delivery: recent advances and future challenges. Ther Deliv (2014) 0.75
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul (1984) 35.22
BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res (2002) 8.55
Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays in culture. Cancer Commun (1991) 6.25
Strategies for silencing human disease using RNA interference. Nat Rev Genet (2007) 5.19
Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol Cancer Ther (2006) 4.57
Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Res (2003) 4.28
Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res (2004) 3.80
Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res (1994) 3.30
Gene silencing by systemic delivery of synthetic siRNAs in adult mice. J Mol Biol (2003) 3.27
Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. Cancer Res (2005) 2.98
Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy. Clin Cancer Res (2006) 2.86
Progress towards in vivo use of siRNAs. Mol Ther (2006) 2.56
Targeted quantum dot conjugates for siRNA delivery. Bioconjug Chem (2007) 2.31
Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development. Cancer Res (2008) 2.18
Mutations of the BRAF gene in benign and malignant melanocytic lesions. J Invest Dermatol (2003) 2.14
Conjugate for efficient delivery of short interfering RNA (siRNA) into mammalian cells. FEBS Lett (2004) 2.13
Effective treatment of cutaneous and subcutaneous malignant tumours by electrochemotherapy. Br J Cancer (1998) 2.11
Melanoma cell lines from different stages of progression and their biological and molecular analyses. Melanoma Res (1997) 2.11
New non-viral method for gene transfer into primary cells. Methods (2004) 2.00
RNA interference: from gene silencing to gene-specific therapeutics. Pharmacol Ther (2005) 1.79
Ultrasound and transdermal drug delivery. Drug Discov Today (2004) 1.61
Systemic delivery of liposomal short-chain ceramide limits solid tumor growth in murine models of breast adenocarcinoma. Clin Cancer Res (2005) 1.60
Loss of PTEN promotes tumor development in malignant melanoma. Cancer Res (2003) 1.58
Targeting mitogen-activated protein kinase/extracellular signal-regulated kinase kinase in the mutant (V600E) B-Raf signaling cascade effectively inhibits melanoma lung metastases. Cancer Res (2006) 1.56
Ultrasound mediated transdermal insulin delivery in pigs using a lightweight transducer. Pharm Res (2007) 1.28
Liposomal delivery enhances short-chain ceramide-induced apoptosis of breast cancer cells. J Pharmacol Exp Ther (2003) 1.28
Diagnosis and treatment of cutaneous melanoma: state of the art 2006. Melanoma Res (2007) 1.27
Growth factors rescue cutaneous melanoma cells from apoptosis induced by knockdown of mutated (V 600 E) B-RAF. Oncogene (2005) 1.20
Systemic delivery of RafsiRNA using cationic cardiolipin liposomes silences Raf-1 expression and inhibits tumor growth in xenograft model of human prostate cancer. Int J Oncol (2005) 1.15
Method of mutation analysis may contribute to discrepancies in reports of (V599E)BRAF mutation frequencies in melanocytic neoplasms. J Invest Dermatol (2004) 1.13
siRNA-containing liposomes modified with polyarginine effectively silence the targeted gene. J Control Release (2006) 1.12
An update of the defensive barrier function of skin. Yonsei Med J (2006) 1.11
Inhibition of phosphatidylinositol-3-kinase and mitogen-activated protein kinase kinase 1/2 prevents melanoma development and promotes melanoma regression in the transgenic TPRas mouse model. Mol Cancer Ther (2006) 1.10
Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases. Br J Cancer (2003) 1.00
Can drug-bearing liposomes penetrate intact skin? J Pharm Pharmacol (2006) 0.89
Short ultrasound exposure times for noninvasive insulin delivery in rats using the lightweight cymbal array. IEEE Trans Ultrason Ferroelectr Freq Control (2004) 0.88
Delivery of small interfering RNA to mammalian cells in culture by using cationic lipid/polymer-based transfection reagents. Methods Enzymol (2005) 0.87
Transducer design for a portable ultrasound enhanced transdermal drug-delivery system. IEEE Trans Ultrason Ferroelectr Freq Control (2002) 0.87
Ultrasound-mediated transdermal transport of insulin in vitro through human skin using novel transducer designs. Ultrasound Med Biol (2003) 0.86
Cellular and molecular biology of human melanoma. Cancer Biol Ther (2002) 0.86
Review of traditional and novel modalities that enhance the permeability of local therapeutics across the stratum corneum. Int J Dermatol (2004) 0.86
Ultrasound-mediated transdermal in vivo transport of insulin with low-profile cymbal arrays. Ultrasound Med Biol (2003) 0.84
Liposomal-encapsulated chemotherapy: preliminary results of a phase I study of a novel liposomal paclitaxel. Oncology (Williston Park) (2001) 0.84
Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Res (2003) 4.28
Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res (2004) 3.80
Diabetic retinopathy: seeing beyond glucose-induced microvascular disease. Diabetes (2006) 3.31
Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. Cancer Res (2005) 2.98
Near-infrared emitting fluorophore-doped calcium phosphate nanoparticles for in vivo imaging of human breast cancer. ACS Nano (2008) 2.41
Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development. Cancer Res (2008) 2.18
eEF-2 kinase dictates cross-talk between autophagy and apoptosis induced by Akt Inhibition, thereby modulating cytotoxicity of novel Akt inhibitor MK-2206. Cancer Res (2011) 2.10
Autophagosomal membrane serves as platform for intracellular death-inducing signaling complex (iDISC)-mediated caspase-8 activation and apoptosis. J Biol Chem (2012) 1.79
Regulation of B-Raf kinase activity by tuberin and Rheb is mammalian target of rapamycin (mTOR)-independent. J Biol Chem (2004) 1.75
A novel human homologue of Drosophila polycomblike gene is up-regulated in multiple cancers. Gene (2004) 1.64
Targeted indocyanine-green-loaded calcium phosphosilicate nanoparticles for in vivo photodynamic therapy of leukemia. ACS Nano (2011) 1.63
The PTEN-AKT3 signaling cascade as a therapeutic target in melanoma. Pigment Cell Melanoma Res (2009) 1.62
Systemic delivery of liposomal short-chain ceramide limits solid tumor growth in murine models of breast adenocarcinoma. Clin Cancer Res (2005) 1.60
Loss of PTEN promotes tumor development in malignant melanoma. Cancer Res (2003) 1.58
Ceramide-induced inhibition of Akt is mediated through protein kinase Czeta: implications for growth arrest. J Biol Chem (2001) 1.58
Targeting mitogen-activated protein kinase/extracellular signal-regulated kinase kinase in the mutant (V600E) B-Raf signaling cascade effectively inhibits melanoma lung metastases. Cancer Res (2006) 1.56
Transiently entrapped circulating tumor cells interact with neutrophils to facilitate lung metastasis development. Cancer Res (2010) 1.55
Ceramide recruits and activates protein kinase C zeta (PKC zeta) within structured membrane microdomains. J Biol Chem (2007) 1.52
PRAS40 deregulates apoptosis in malignant melanoma. Cancer Res (2007) 1.52
Bif-1 regulates Atg9 trafficking by mediating the fission of Golgi membranes during autophagy. Autophagy (2011) 1.44
Sphingolipids: regulators of crosstalk between apoptosis and autophagy. J Lipid Res (2012) 1.40
Rheb inhibits C-raf activity and B-raf/C-raf heterodimerization. J Biol Chem (2006) 1.36
Minimally invasive total knee arthroplasty. J Bone Joint Surg Am (2004) 1.36
Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail. Biochem Pharmacol (2010) 1.36
Targeting mutant (V600E) B-Raf in melanoma interrupts immunoediting of leukocyte functions and melanoma extravasation. Cancer Res (2007) 1.31
Characterization of insulin signaling in rat retina in vivo and ex vivo. Am J Physiol Endocrinol Metab (2003) 1.29
Ultrasound mediated transdermal insulin delivery in pigs using a lightweight transducer. Pharm Res (2007) 1.28
Liposomal delivery enhances short-chain ceramide-induced apoptosis of breast cancer cells. J Pharmacol Exp Ther (2003) 1.28
Rapid distribution of liposomal short-chain ceramide in vitro and in vivo. Drug Metab Dispos (2008) 1.24
Encapsulation of organic molecules in calcium phosphate nanocomposite particles for intracellular imaging and drug delivery. Nano Lett (2008) 1.23
Dysregulation of sphingolipid metabolism in cancer. Cancer Biol Ther (2011) 1.22
Targeting Akt3 signaling in malignant melanoma using isoselenocyanates. Clin Cancer Res (2009) 1.22
Combining nanoliposomal ceramide with sorafenib synergistically inhibits melanoma and breast cancer cell survival to decrease tumor development. Clin Cancer Res (2008) 1.22
Use of high performance liquid chromatography-electrospray ionization-tandem mass spectrometry for the analysis of ceramide-1-phosphate levels. J Lipid Res (2009) 1.21
Circulating sphingolipid biomarkers in models of type 1 diabetes. J Lipid Res (2010) 1.21
Is B-Raf a good therapeutic target for melanoma and other malignancies? Cancer Res (2008) 1.18
Toll-like receptors at the ocular surface. Ocul Surf (2008) 1.18
Clinical experience using a minimally invasive surgical approach for total knee arthroplasty: early results of a prospective randomized study compared to a standard approach. J Arthroplasty (2007) 1.16
KLF6 Gene and early melanoma development in a collagen I-rich extracellular environment. J Natl Cancer Inst (2010) 1.14
Method of mutation analysis may contribute to discrepancies in reports of (V599E)BRAF mutation frequencies in melanocytic neoplasms. J Invest Dermatol (2004) 1.13
Nanoparticulate alternatives for drug delivery. ACS Nano (2010) 1.13
Diabetes alters sphingolipid metabolism in the retina: a potential mechanism of cell death in diabetic retinopathy. Diabetes (2006) 1.13
Intravenous delivery of siRNA targeting CD47 effectively inhibits melanoma tumor growth and lung metastasis. Mol Ther (2013) 1.12
Phosphatidic acid mediates activation of mTORC1 through the ERK signaling pathway. Am J Physiol Cell Physiol (2010) 1.12
Calcium phosphate nanocomposite particles for in vitro imaging and encapsulated chemotherapeutic drug delivery to cancer cells. Nano Lett (2008) 1.12
Tumor suppression by PTEN requires the activation of the PKR-eIF2alpha phosphorylation pathway. Sci Signal (2009) 1.11
Peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) ligands inhibit growth of UACC903 and MCF7 human cancer cell lines. Toxicology (2007) 1.09
Targeting of survivin by nanoliposomal ceramide induces complete remission in a rat model of NK-LGL leukemia. Blood (2010) 1.09
Robust activation of the human but not mouse telomerase gene during the induction of pluripotency. FASEB J (2010) 1.07
Therapeutic efficacy of FTY720 in a rat model of NK-cell leukemia. Blood (2011) 1.03
Nanoliposomal ceramide prevents in vivo growth of hepatocellular carcinoma. Gut (2010) 1.02
Formation and role of exosomes in cancer. Cell Mol Life Sci (2014) 1.02
Vemurafenib (PLX4032): an orally available inhibitor of mutated BRAF for the treatment of metastatic melanoma. Ann Pharmacother (2011) 1.02
State-dependent block of HERG potassium channels by R-roscovitine: implications for cancer therapy. Am J Physiol Cell Physiol (2009) 1.00
Ptena and ptenb genes play distinct roles in zebrafish embryogenesis. Dev Dyn (2005) 1.00
Paralemmin interacts with D3 dopamine receptors: implications for membrane localization and cAMP signaling. Arch Biochem Biophys (2005) 0.99
Synthesis and anticancer activity comparison of phenylalkyl isoselenocyanates with corresponding naturally occurring and synthetic isothiocyanates. J Med Chem (2008) 0.99
Glucose measurements with sensors and ultrasound. Ultrasound Med Biol (2005) 0.99
Bioconjugation of calcium phosphosilicate composite nanoparticles for selective targeting of human breast and pancreatic cancers in vivo. ACS Nano (2010) 0.99
Toxicological considerations when creating nanoparticle-based drugs and drug delivery systems. Expert Opin Drug Metab Toxicol (2011) 0.98
Metabolism of short-chain ceramide by human cancer cells--implications for therapeutic approaches. Biochem Pharmacol (2010) 0.98
Inhibition of corneal inflammation by liposomal delivery of short-chain, C-6 ceramide. J Leukoc Biol (2008) 0.97
Ceramide-based therapeutics for the treatment of cancer. Anticancer Agents Med Chem (2011) 0.95
Sequential binding of αVβ3 and ICAM-1 determines fibrin-mediated melanoma capture and stable adhesion to CD11b/CD18 on neutrophils. J Immunol (2010) 0.95
Growth of human pancreatic cancer is inhibited by down-regulation of gastrin gene expression. Pancreas (2009) 0.95
Calcium phosphate-based composite nanoparticles in bioimaging and therapeutic delivery applications. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2011) 0.94
PBISe, a novel selenium-containing drug for the treatment of malignant melanoma. Mol Cancer Ther (2008) 0.94
Realizing the clinical potential of cancer nanotechnology by minimizing toxicologic and targeted delivery concerns. Cancer Res (2012) 0.94
Regression of established hepatocellular carcinoma is induced by chemoimmunotherapy in an orthotopic murine model. Hepatology (2012) 0.93
Melanoma chemoprevention in skin reconstructs and mouse xenografts using isoselenocyanate-4. Cancer Prev Res (Phila) (2010) 0.93
Combinatorial therapies improve the therapeutic efficacy of nanoliposomal ceramide for pancreatic cancer. Cancer Biol Ther (2011) 0.93
Propagation of undifferentiated human embryonic stem cells with nano-liposomal ceramide. Stem Cells Dev (2010) 0.92
Regulation of UDP-glucuronosyltransferase 1A1 expression and activity by microRNA 491-3p. J Pharmacol Exp Ther (2014) 0.92
Identification of glycogen synthase kinase 3α as a therapeutic target in melanoma. Pigment Cell Melanoma Res (2013) 0.91
Macrophage inhibitory cytokine-1 regulates melanoma vascular development. Am J Pathol (2010) 0.91
Delivery of PAR-4 plasmid in vivo via nanoliposomes sensitizes colon tumor cells subcutaneously implanted into nude mice to 5-FU. Cancer Biol Ther (2009) 0.91
Use of liposomes as drug delivery vehicles for treatment of melanoma. Pigment Cell Melanoma Res (2009) 0.90